ESG Implemenation Consulting Services

AGP Wins Silver Award at the SAFA Best Presented Annual Report Awards 2024

AGP Wins 1st Position in Pharmaceutical Category at BCSR Awards 2024 — for the Second Consecutive Year!

AGP Celebrates Dual Recognition at the 8th Pakistan Pharma Summit & PESA Awards 2025

AGP Receives the 22nd Annual Environment Excellence Award 2025

AGP Wins GDEIB Awards in Nine Categories

AGP x TrashIt Sustainability Training

AGP x Cyber Security Awareness Training

AGP x Cancer Foundation Hospital: Breast Cancer Awareness Session

AGP Visits Karachi Down Syndrome Program (KDSP)

Diwali Celebration at AGP: Honoring Diversity, Culture & Togetherness

AGP Limited Secures 1st Position at BCSR Awards 2023

AGP collaborates with Childlife Foundation on Children’s Day 2023

AGP Launched Peridots – A Thanda Solution to Acidity, Gas and Indigestion

AGP secures 2nd Position at BCR Awards 2022

AGP wins Top Exporter Award at 6th PPMA Summit

AGP sponsors KDSP Carnival 2023

AGP bags big win at GDEIB Awards 2023

AGP continues partnership with IBA

AGP continues collaboration with TCF

AGP joins hands with SKMF

AGP continues partnership with ACF

AGP conducts Allergy Awareness Session At Pak Turk Maarif

Gong-Ringing Ceremony of AGP at PSX

Urso

Generic:

Ursodeoxycholic acid

 

Therapeutic Class:

Bile Stone Therapy
 

Composition:

  • Each capsule of Urso contains
  • 250 mg or 500 mg Ursodeoxycholic acid as the active ingredient.
  • Each 5 ml of Urso Suspension contains 250 mg of Ursodeoxycholic acid
 

Description:

Urso contains Ursodeoxycholic acid that has been used successfully for oral dissolution therapy of gallstones and in the treatment of bile reflux gastritis. It also reduces
the symptoms and improves hepatic enzyme levels in patients with primary biliary cirrhosis. There are number of cholestatic diseases (primary sclerosing cholangitis, the various forms of hepatitis including overlap syndrome, cholestasis occurring in patients receiving total parenteral nutrition and in cholestatic diseases of childhood such as cystic fibrosis) in which positive effects of treatment with Urso have been published.

 

Indications:

• For the dissolution of radiolucent cholesterol gallstones (no larger than 15 mm in diameter) in the patients with still functioning gall bladder despite the gallstones

• For the symptomatic therapy of primary biliary cirrhosis, provided there is no decompensated hepatic cirrhosis

• For the treatment of bile reflux gastritis

 

Dosage:

 

Dosage for Urso capsule:

 

For the dissolution of cholesterol gallstones:

The daily dosage amounts to 10 mg per kg body weight. Swallow the capsules whole with a little fluid, do not chew. Do take the capsules regularly. Gallstones generally take from 6 to 24 months to dissolve. If the gallstones have not become smaller after 12 months, do not continue treatment. The result of therapy should be mentioned by ultrasonography or X-ray every 6 months. At the follow-up examinations, a check should be made to see  whether calcification of the stones has occurred in the meantime. Should this be the case, the treatment must be ended.

 

For the treatment of primary biliary cirrhosis (PBC):

The daily dosage is 10-15 mg per kg body weight daily. For the first 3 months of treatment, Urso caps should be taken divided over the day. With improvement of the liver values the daily dose may be taken once daily in the evening. The use of Urso capsule in primary biliary cirrhosis may be  continued indefinitely. In patients with primary biliary cirrhosis, in rare cases the clinical symptoms may worsen at the beginning of treatment, e.g.  the itching may increase. Should this occur, therapy should first be continued with Urso caps 250 mg daily, and the therapy gradually increased until the dose indicated in the respective dosage regimen is reached again.

 

For the treatment of bile reflux gastritis: 

Urso caps 250 mg should normally be taken for 10-14 days. The attending physician will decide how long treatment should be continued.
Note: It is important for the result of treatment to take the capsules regularly. Liver function parameters should be monitored several times during treatment.

 

For the symptomatic treatment of primary biliary cirrhosis:

The daily dose depends on bodyweight and is approx. 2 to 6 capsule (10 to 15 mg Ursodeoxycholic acid per kg bodyweight)

 

Dosage for Urso Suspension:

There are no age restrictions on the use of Urso 250mg/5ml suspension

 

For the treatment of primary biliary cirrhosis (PBC):

The usual daily dose depends on body weight, and is approximately 14 ± 2 mg Ursodeoxycholic acid per kg of body weight. One Teaspoonful (= 5 ml oral suspension) contains 250 mg of Ursodeoxycholic acid.

For the first 3 months of treatment, Urso 250 mg/5 ml suspension should be taken divided over the day. When the liver function parameters improve, the daily dose can be administered once a day in the evening.

Urso 250 mg/5 ml suspension should be taken in accordance with the dosage regimen given above. The oral suspension must be taken regularly. The use of Urso 250 mg/5 ml suspension in primary biliary cirrhosis may be continued indefinitely. In patients with primary biliary cirrhosis, in rare cases the clinical symptoms may worsen at the beginning of treatment, e.g. the itching may increase. Should this occur, therapy should first be
continued with a reduced daily dose of Urso suspension, and the dose then gradually increased (increase of the daily dose weekly) until the dose indicated in the respective dosage regimen is reached again.

 

Dissolution of Gallstones: 

Approximately 10 mg of Ursodeoxycholic acid per kg of body weight daily, equivalent to:
One Teaspoonful (= 5 ml oral suspension) contains 250 mg of Ursodeoxycholic acid. Urso suspension should be taken in the evening at bedtime. The oral suspension must be taken regularly. The time required for dissolution of gallstones is likely to range from 6 to 24 months depending on stone size and composition. Follow-up cholecystograms or ultrasound investigation may be useful at 6 month intervals until the gallstones have disappeared. Treatment should be continued until 2 successive cholecystograms and/or ultrasound investigations 4-12 weeks apart have failed to demonstrate gallstones. This is because these techniques do not permit reliable visualization of stones less than 2mm in diameter. The likelihood of recurrence of gallstones after dissolution by bile acid treatment has been estimated as up to 50% at 5 years. The efficiency of Urso in treating radio-opaque or partially radio-opaque gallstones has not been tested but these are generally thought to be less soluble than radiolucent stones. Non-cholesterol stones account for 10-15% of radiolucent stones and may not be dissolved by bile acids.

 

Elderly:

There is no evidenceto suggest that any alteration in the adult dose is needed but the relevant precautions should be taken into account.

Children: 

Cholesterol rich gallstones are rare in children but when they occur, dosage should be related to bodyweight.

 

Presentations:

  • 250 mg caps 10’s,
  • 500 mg caps 10’s,
  • 250 mg/5 ml susp 120 ml,

 


 
    

Urgesin

Generic

Solifenacin Succinate

Therapeutic Class:

Urinary Incontinence Prd

 

Composition:

Each Urgesin tab contains 5 mg
or 10 mg of solifenacin succinate.

 

Description:

Urgesin (Solifenacin) is used to
treat contraction of overactive bladder with associated problems such as
increased urination frequency and urge incontinence.

 

Indications:

Urgesin is a muscarinic
antagonist indicated for the treatment of overactive bladder with symptoms
of urge urinary incontinence, urgency and urinary frequency.

 

Dosage:

The recommended dose of Urgesin
is 5 mg once daily. If the 5 mg dose is well tolerated, the dose may be
increased to 10 mg once daily.

 

Presentations:

  • Urgesin 5 mg tab is available in pack of 10’s.
  • Urgesin 10 mg Tab is available in pack of 10’s.

 

Toni-5

Generic:

Phosphoric acid, Lysine , Monohydrate, Dimethyl amino ethanol, Sorbitol, Calcium , gluconoglucoheptonate

 

Therapeutic Class:

TONICS

 

Composition:

Each 5 ml contains

  • Lysine monohydrochloride (PFM Specs.) ………………… 200 mg
  • Calcium gluconoglucoheptonate (Ph. Eur.)………………..150 mg
  • Dimethyl-amino-ethanol (pyro) glutamate (PFM Specs.)…. 50 mg
  • Phosphoric acid (Ph. Eur.)………………………………… 0.025 ml
  • Sorbitol……………………………………………………. 750 mg
 

Description:

Toni-5 syrup combines various factors to stimulate growth in young children.Dimethylaminoethanol (pyro) glutamate, which acts on interneuronal transmissions.Lysine. calcium and phosphorus, which promote growth of muscles & bone tissues in length & weight

 

Indications:

  • Fatigue of any nature (growth disorders, anorexia, malnutrition)
  • Asthenia
  • Decreased Alertness
  • Convalescence
  • General Weakness
 

Dosage:

 

Usual dosage: 1 teaspoonful/ 5 kg body weight daily in 2-3 divided doses.

 

The following  daily dosages should be divided 2-3 times or as directed by the physician.

 

For neonates: 1 teaspoonful/ 5 kg body weight.

Before 6 months of age: 1 teaspoonful .

From 6 to 12 months of age: 2 teaspoonfuls.

From 12 months to 6 years of age: 3 teaspoonfuls.

Above 6 years of age: 4 to 6 teaspoonfuls.

 

Presentations:

120 ml syrup

 

Spasler P

Generic:

Hyoscine Butyl Bromide

 

Therapeutic Class:

Antispasmodic and Anticholinergic Plain

 

Composition:

Each 5 ml of Spasler-P syrup contains

  • hyoscine butyl bromide (B.P.) 5 mg
 

Description:

Spasler P syrup has a selective
antispasmodic effect on the smooth muscles of the gastrointestinal, biliary
and urogenital tracts. It has the great advantage that despite its
antispasmodic effect it is virtually devoid of the side effects usually
associated with atropine like drugs

 

Indications:

For the short term treatment of

  • Colics due to renal and
    biliary calculi
  • Acute pain due to spasm of
    bile duct, urinary passage or gastro-intestinal tract
  • Pancreatitis
  • Pains of uncertain genesis
    in the abdominal region
  • Postoperative pain
  • Spastic conditions of the
    female genital system
 

Dosage:

Infant: 1 teaspoon 3 times daily

1- 6 years: 1-2 teaspoons 3 times daily

Over 6 years: 2 teaspoons 3-5 times daily

 

Presentations:

  • 5 mg/5 ml syrup 60 ml

 


Spasler Neo

Generic:

Mebeverine HCl

 

Therapeutic Class:

Antispasmodic and Anticholinergic Plain

 

Composition:

Each Spasler Neo tablet contains

  • mebeverine hydrochloride B.P 135 mg
 

Description:

Spasler Neo is myotropic
antispasmodic, which acts through specific action on smooth muscles of
gastrointestinal tract. It does not affect autonomic nervous system,
therefore its use is not associated with usual anticholinergic side
effects. For this reason Spasler Neo can be prescribed in patients
suffering from BPH or glaucoma

 

Indications:

  • Irritable bowel syndrome
    associated with diarrhoea or constipation
  • Alternating constipation
    with diarrhoea
  • Abdominal distension
  • GI spasm associated with
    organic diseases like diverticulitis, regional enteritis, duodenal
    ulcer and dysentery
  • Biliary dyskinesia
 

Dosage:

The usual recommended dosage of
Spasler Neo is one tablet of 135 mg three times daily. The tablet should
preferably be taken 20 minutes before meals

 

Presentations:

  • 135 mg tab 30’s

 


Sinaxamol

Generic:

Orphenadrine Citrate, Paracetamol

 

Therapeutic Class:

Muscle relaxants central

 

Composition:

Each film-coated tablet of
Sinaxamol contains:

 

  • Orphenadrine Citrate B. P…….35 mg
  • Paracetamol B.P……450 mg
 

Description:

Sinaxamol tablet contains
orphenadrine citrate and paracetamol, the combined muscle relaxant action
of orphenadrine citrate and the analgesic effect of paracetamol provides
in-depth relief from pain associated with skeletal muscle spasm. Orphenadrine
Citrate is an centrally effective muscle relaxant. It is readily absorbed
from the gastro-intestinal tract and is almost completely metabolized.
Paracetamol possess analgesic and antipyretic actions.

 

Indications:

Any condition involving skeletal
muscle spasm secondary to

  • Acute trauma
  • Herniated disc
  • Fibrositis characterized by low back pain
  • Muscular strains and pain
  • Sciatica
  • Stiff neck
  • Muscular rheumatism
  • Muscular spasm found in frozen shoulder
  • Arthritis
  • Bursitis
  • Sprains
  • Acute torticollis
  • Contusions
  • Acute traumatic lumbar strain
  • Osteoarthritis
  • Dysmenorrhoea
 

Dosage:

 

Adults: Two tablets of Sinaxamol three times daily

Children: Not recommended

 

Presentations:

  • Sinaxamol tab 100’s

 

 

Sinaxamol Extra

Generic:

Paracetamol, Orphenadrine
Citrate

 

Therapeutic Class:

Muscle relaxants central

 

Composition:

Each tablet of Sinaxamol Extra
contains:

 

  • Orphenadrine Citrate B. P………..50 mg
  • Paracetamol B.P……………650 mg
 

Description:

Sinaxamol Extra contains
orphenadrine citrate and paracetamol, the combined muscle relaxant action
of orphenadrine citrate and the analgesic effect of paracetamol provides
in-depth relief from pain associated with skeletal muscle spasm.
Orphenadrine Citrate is an centrally effective muscle relaxant. It is
readily absorbed from the gastro-intestinal tract and is almost completely
metabolized. Paracetamol possess analgesic and antipyretic actions.

 

Indications:

Any condition involving skeletal
muscle spasm secondary to

  • Acute trauma
  • Herniated disc
  • Fibrositis characterized by
    low back pain
  • Muscular strains and pain
  • Sciatica
  • Stiff neck
  • Muscular rheumatism
  • Muscular spasm found in
    frozen shoulder
  • Arthritis
  • Bursitis
  • Sprains
  • Acute torticollis
  • Contusions
  • Acute traumatic lumbar
    strain
  • Osteoarthritis
  • Dysmenorrhoea
 

Dosage:

Adults: One tablet of Sinaxamol Extra twice daily.

Children: Not recommended

 

Presentations:

  • Sinaxamol Extra tab 30’s

 

Rubiject Injection

Generic:

Iron sucrose

 

Therapeutic Class:

Iron Plain

 

Composition:

Each 5 ml of Rubiject ampoule
contains:
Iron sucrose equivalent to elemental iron … 100 mg

 

Description:

Rubiject (iron sucrose
injection) is an aqueous complex of polynuclear iron (III)-hydroxide in
sucrose for intravenous use.

 

Indications:

Rubiject is recommended in:

  • Conditions in which there
    is clinical requirement for rapid iron supply
  • Active inflammatory bowel
    disease where oral iron preparations are ineffective
  • Iron deficiency due to
    other reasons like final stages of pregnancy, non-responsiveness or
    non-compliance to oral iron therapy, malabsorption, before and after
    surgery etc.

Rubiject is also indicated in
the treatment of iron deficiency anaemia in chronic kidney disease patients
who are:

  • Non-dialysis dependent
    patients receiving or not receiving an erythropoietin
  • Peritoneal dialysis
    dependent / hemodialysis dependent patients who are receiving an
    erythropoietin
 

Dosage:

Adults:
Rubiject injection 5-10 ml (100-200 mg iron) 1-3 times / week depending on
the haemoglobin level.
Rubiject injection should be administered intravenously by slow injection
or infusion.

Children:
Under study conditions, there is limited data available. If there is
clinical requirement, Rubiject is recommended not to exceed 0.15 ml (3 mg
iron)/kg body weight 1-3 times/week depending on the haemoglobin level
also.

Recommended Adult Dosage(Chronic kidney disease patients):

Hemodialysis Dependent:
Undiluted Rubiject can be administered as 100 mg slow IV injection in 2-5
minutes or as an infusion of 100 mg, diluted in a maximum of 100 ml of 0.9%
NaCl in atleast 15 minutes per consecutive hemodialysis session for a total
dose of 1000 mg.

Non-Dialysis Dependent:
Rubiject is administered as a total dose of 1000 mg in 14 days as 200 mg
slow IV injection undiluted in 2-5 minutes on 5 different occasions within
14 days.

Peritoneal Dialysis Dependent:
Rubiject administered as a total dose of 1000 mg in 3 divided doses, given by slow IV infusion, within 28 days: 2 infusions of 300 mg in 1½ hours 14 days apart followed by one 400 mg infusion in 2½ hours 14 days later. The Rubiject dose should be diluted in a maximum of 250 ml of 0.9% NaCl. .

 

Presentations:

  • Inj 5′s

 


Rigix

Generic:

Cetirizine Dihydrochloride

 

Therapeutic Class:

Antihistamines Systemic

 

Composition:

Each Rigix tablet contains cetirizine dihydrochloride 10 mg.
Each ml of Rigix oral solution contains 1 mg of cetirizine dihydrochloride
 

Description:

Cetirizine, an active metabolite
of hydroxyzine, is an antihistamine; its principal effects are mediated via
selective inhibition of peripheral H1 receptors and are indicated in
allergic conditions

 

Indications:

  • Seasonal allergic rhinitis
  • Perennial allergic rhinitis
  • Chronic idiopathic urticaria
 

Dosage:

Tablets:
Adults & children above 12 years: One 10 mg tablet dailyRigix oral solution can be taken without regard to food consumption.

Children 6 months to <2 years for Perennial Allergic Rhinitis and Chronic Urticaria:

The recommended dose of Rigix oral solution in children 6 months to 23 months of age is 2.5 mg (½ teaspoonful) once daily. The dose in children 12 to 23 months of age can be increased to a maximum dose of 5 mg per day, given as ½ teaspoonful (2.5 mg) every 12 hours.

Children 2 to 5 years for Chronic Urticaria:

The recommended initial dose of Rigix oral solution in children aged 2 to 5 years is 2.5 mg (½ teaspoonful) once daily. The dosage in this age group can be increased to a maximum dose of 5 mg per day given as 1 teaspoonful (5 mg) once daily, or as ½ teaspoonful (2.5 mg) given every 12 hours.

Children 6 years & above:

2 teaspoonfuls once daily or 1 teaspoonful twice daily.

 

 

Presentations:

  • 10 mg tabs 30’s,
  • Oral sol 120ml,

Protege

Generic:

Lactobacillus acidophilus,
Lactobacillus rhamnosus, Bifidobacterium lactis, Bifidobacterium bifidum,
Galactooligosaccharide

 

Therapeutic Class:

Antidiarrheal Microorganisms

 

Composition:


Each 2 g Sachet of Protégé is a blend of 4 different strains with 10 billion COLONY FORMING UNITS of human gut flora like friendly bacteria include:

  • Lactobacillus acidophilus 
  • Lactobacillus rhamnosus
  • Bifidobacterium lactis
  • Bifidobacterium bifidum
  • A PREBIOTIC Galactooligosaccharide (GOS) 
  • Lactobacillus acidophilus

Description:


Protégé is Probiotic preparation. Probiotics are live microorganisms which when administered in adequate amounts, they confer a health benefit on the host. Popular probiotic strains include the Lactobacillus spp., Bifidobacterium spp. and coccus spp.

 

Indications:

  • Acute & Chronic Infectious Diarrhea
  • Traveler’s Diarrhea
  • Antibiotic associated Diarrhea
  • Inflammatory Bowel Disease (IBS)
  • Lactose Intolerance
 

Dosage:


Children & Adult: Take 1
2
sachets per time, dissolving into water with temperature not more than 40
.

 

Presentations:

  • 2 g Sachet 10’s,